Figure 6.

ORco competition assays as dose-dependent antagonist effect.A, the IC₅₀ values determined for carvacrol (CRV) in the presence of 50 and 150 μM ORcoRAM2 were 26.3 μM (pIC₅₀: 4.58001 ± 0.21732, R²: 0.99998) and 28.4 μM (pIC₅₀: 4.54608, R²: 0.99747), respectively. There is no significant change in the IC₅₀ as the ORco agonist (OA) concentration increases (IC₅₀ of CRV with 100 μM OA is 23.4 μM), expected when compounds bind to different binding sites, with allosteric antagonistic effect. B, the IC₅₀ values determined for octadienal (OCT) in the presence of 50 and 150 μM ORcoRAM2 were 41.8 μM (pIC₅₀: 4.37887 ± 0.03444, R²: 0.99999) and 116.8 μM (pIC₅₀: 3.93263 ± 0.26793, R²: 0.99973), respectively. There is a dextral shift of the curve and a concomitant increase of the IC₅₀ as the OA concentration is increased, expected when both compounds compete for the same binding site. C, the IC₅₀ values determined for cumin alcohol (CA) in the presence of 50 and 150 μM ORcoRAM2 were 84.7 μM (pIC₅₀: 4.07226 ± 0.23144, R²: 0.99998) and 77.8 μM (pIC₅₀: 4.10898 ± 0.17809, R²: 0.99984), respectively. Error bars indicate mean ± SE. Data points were normalized to the maximum value (set at 100%).